On November 19, 2019 Palleon Pharmaceuticals, a leading biotech company developing drugs that target the Siglec-Sialoglycan axis to treat cancer, reported that it will present preclinical data from two of its development programs today at the 11th Annual Protein & Antibody Engineering Summit (PEGS Europe) in Lisbon, Portugal (Press release, Palleon Pharmaceuticals, NOV 19, 2019, View Source [SID1234551483]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Siglec-Sialoglycan axis, a previously underappreciated mechanism of immunosuppression in cancer, has recently emerged as a major tumor immune escape pathway. Palleon has leveraged its proprietary EAGLE and CONVERGENCE platforms to develop a suite of technologies that target both Siglec receptors and their sialoglycan ligands.
Li Peng, Ph.D., Senior Vice President of Research and Early Product Development at Palleon, will present preclinical data on the company’s lead candidate EAGLE-Her2, showing that selectively removing the terminal sialic acids of sialoglycans within the tumor microenvironment effectively inhibits the Siglec-Sialoglycan immune checkpoint and reinvigorates both the innate and adaptive responses to cancer. In addition, Dr. Peng will present Palleon’s anti-Siglec-9 monoclonal antibody program, including preclinical studies that detail the development of antagonistic anti-Siglec antibodies that block the Siglec-Sialoglycan axis.
Palleon Scientific Advisor, Joy Burchell, Ph.D. and Professor of Glyco-Oncology at Kings College London will also present at PEGS Europe. Dr. Burchell will discuss the role of a glycosylated form of tumor-associated mucin MUC1, which engages with Siglec-9 on monocytes and macrophages to create an immunosuppressive tumor microenvironment.
"Targeting the Siglec-Sialoglycan axis of immunosuppression is a truly novel approach to treating cancer that could potentially benefit patients who are resistant to first-generation immuno-oncology therapies," said Jim Broderick, M.D., Chief Executive Officer and Founder of Palleon. "Our preclinical data demonstrates striking single agent efficacy across a range of animal models and human in vitro systems."